Cargando…
Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes
Hereditary pancreatic cancer, which includes patients with familial pancreatic cancer (FPC) and hereditary pancreatic cancer syndromes, accounts for about 10% of all pancreatic cancer diagnoses. The early detection of pre-cancerous pancreatic cysts has increasingly become a focus of interest in rece...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313108/ https://www.ncbi.nlm.nih.gov/pubmed/35884779 http://dx.doi.org/10.3390/biomedicines10071475 |
_version_ | 1784753998243299328 |
---|---|
author | Ardeshna, Devarshi R. Rangwani, Shiva Cao, Troy Pawlik, Timothy M. Stanich, Peter P. Krishna, Somashekar G. |
author_facet | Ardeshna, Devarshi R. Rangwani, Shiva Cao, Troy Pawlik, Timothy M. Stanich, Peter P. Krishna, Somashekar G. |
author_sort | Ardeshna, Devarshi R. |
collection | PubMed |
description | Hereditary pancreatic cancer, which includes patients with familial pancreatic cancer (FPC) and hereditary pancreatic cancer syndromes, accounts for about 10% of all pancreatic cancer diagnoses. The early detection of pre-cancerous pancreatic cysts has increasingly become a focus of interest in recent years as a potential avenue to lower pancreatic cancer incidence and mortality. Intraductal papillary mucinous cystic neoplasms (IPMNs) are recognized precursor lesions of pancreatic cancer. IPMNs have high prevalence in patients with hereditary pancreatic cancer and their relatives. While various somatic mutations have been identified in IPMNs, certain germline mutations associated with hereditary cancer syndromes have also been identified in IPMNs, suggesting a role in their formation. While the significance for the higher prevalence of IPMNs or similar germline mutations in these high-risk patients remain unclear, IPMNs do represent pre-malignant lesions that need close surveillance. This review summarizes the available literature on the incidence and prevalence of IPMNs in inherited genetic predisposition syndromes and FPC and speculates if IPMN and pancreatic cancer surveillance in these high-risk individuals needs to change. |
format | Online Article Text |
id | pubmed-9313108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93131082022-07-26 Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes Ardeshna, Devarshi R. Rangwani, Shiva Cao, Troy Pawlik, Timothy M. Stanich, Peter P. Krishna, Somashekar G. Biomedicines Review Hereditary pancreatic cancer, which includes patients with familial pancreatic cancer (FPC) and hereditary pancreatic cancer syndromes, accounts for about 10% of all pancreatic cancer diagnoses. The early detection of pre-cancerous pancreatic cysts has increasingly become a focus of interest in recent years as a potential avenue to lower pancreatic cancer incidence and mortality. Intraductal papillary mucinous cystic neoplasms (IPMNs) are recognized precursor lesions of pancreatic cancer. IPMNs have high prevalence in patients with hereditary pancreatic cancer and their relatives. While various somatic mutations have been identified in IPMNs, certain germline mutations associated with hereditary cancer syndromes have also been identified in IPMNs, suggesting a role in their formation. While the significance for the higher prevalence of IPMNs or similar germline mutations in these high-risk patients remain unclear, IPMNs do represent pre-malignant lesions that need close surveillance. This review summarizes the available literature on the incidence and prevalence of IPMNs in inherited genetic predisposition syndromes and FPC and speculates if IPMN and pancreatic cancer surveillance in these high-risk individuals needs to change. MDPI 2022-06-22 /pmc/articles/PMC9313108/ /pubmed/35884779 http://dx.doi.org/10.3390/biomedicines10071475 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ardeshna, Devarshi R. Rangwani, Shiva Cao, Troy Pawlik, Timothy M. Stanich, Peter P. Krishna, Somashekar G. Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes |
title | Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes |
title_full | Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes |
title_fullStr | Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes |
title_full_unstemmed | Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes |
title_short | Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes |
title_sort | intraductal papillary mucinous neoplasms in hereditary cancer syndromes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313108/ https://www.ncbi.nlm.nih.gov/pubmed/35884779 http://dx.doi.org/10.3390/biomedicines10071475 |
work_keys_str_mv | AT ardeshnadevarshir intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes AT rangwanishiva intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes AT caotroy intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes AT pawliktimothym intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes AT stanichpeterp intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes AT krishnasomashekarg intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes |